Page last updated: 2024-10-24

regulation of circadian sleep/wake cycle, wakefulness

Definition

Target type: biologicalprocess

Any process that modulates the rate, frequency, or extent of the wakeful phase of the circadian sleep/wake cycle. The wakeful phase is the part of the circadian sleep/wake cycle where the organism is not asleep. [GOC:dph, GOC:tb]

The circadian sleep/wake cycle, also known as the "biological clock," is a complex and tightly regulated process that governs the cyclical patterns of sleep and wakefulness over a roughly 24-hour period. This internal timing system is essential for maintaining physiological homeostasis and coordinating various biological functions with the environment.

The regulation of the circadian sleep/wake cycle involves a sophisticated interplay of several key components:

1. **Central Pacemaker:** The suprachiasmatic nucleus (SCN) in the hypothalamus acts as the master circadian clock. It receives light signals from the eyes through the retinohypothalamic tract, which synchronizes the internal clock with the external environment (light/dark cycle). The SCN generates a rhythm of electrical and biochemical activity that oscillates approximately every 24 hours, influencing the timing of various physiological processes, including sleep-wake patterns.

2. **Molecular Oscillators:** Within the SCN, specific genes and proteins, known as clock genes, form a molecular feedback loop that regulates the circadian rhythm. These genes, including Clock, Bmal1, Per1/2, and Cry1/2, interact in a complex cascade of transcription and translation. They exhibit a rhythmic expression pattern, ensuring a 24-hour oscillation.

3. **Peripheral Oscillators:** While the SCN is the primary pacemaker, other tissues and organs also possess their own circadian clocks, called peripheral oscillators. These clocks are influenced by the central clock in the SCN, as well as local cues like food intake and temperature. They contribute to the regulation of organ-specific functions and contribute to the overall circadian rhythm.

4. **Neurotransmitters and Hormones:** The SCN communicates with other brain regions and peripheral tissues through the release of neurotransmitters and hormones, including melatonin, cortisol, and orexin. These signaling molecules play crucial roles in regulating sleep and wakefulness. For instance, melatonin, secreted by the pineal gland under the influence of the SCN, promotes sleepiness at night, while cortisol, released from the adrenal glands, promotes alertness in the morning.

5. **Sleep-Promoting and Wake-Promoting Systems:** The brain possesses distinct neural pathways involved in promoting sleep and wakefulness. The ventrolateral preoptic nucleus (VLPO), a sleep-promoting region, inhibits wake-promoting areas. Conversely, the orexin/hypocretin neurons in the hypothalamus, along with other wake-promoting regions, promote alertness and arousal. The balance between these systems determines the transition between sleep and wakefulness.

The circadian sleep/wake cycle is essential for maintaining optimal physiological function, regulating hormone production, and coordinating various bodily processes. Disruptions to this cycle, known as circadian rhythm disorders, can lead to a range of health problems including sleep disturbances, mood disorders, metabolic disorders, and increased risk of chronic diseases.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Orexin receptor type 2An orexin receptor type 2 that is encoded in the genome of human. [PRO:DNx, UniProtKB:O43614]Homo sapiens (human)

Compounds (14)

CompoundDefinitionClassesRoles
sb 408124SB 408124: a hypocretin receptor type 1 (HcrtR1) antagonistorganohalogen compound;
quinolines
sb 334867-a1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea: selective OX1 receptor antagonistnaphthyridine derivative
jnj 10397049JNJ 10397049: a selective orexin receptor-2 antagonist
sb674042SB674042: nonpeptide antagonist to the human orexin-1 receptor; structure in first source
tcs ox2 29
almorexantalmorexant: a dual orexin receptor antagonist for treatment of insomniaisoquinolines
suvorexantsuvorexant : An aromatic amide obtained by formal condensation of the carboxy group of 5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid with the secondary amino group of 5-chloro-2-[(5R)-5-methyl-1,4-diazepan-1-yl]-1,3-benzoxazole. An orexin receptor antagonist used for the management of insomnia.

suvorexant: an orexin receptor antagonist; structure in first source
1,3-benzoxazoles;
aromatic amide;
diazepine;
organochlorine compound;
triazoles
central nervous system depressant;
orexin receptor antagonist
mk-6096MK-6096: antagonist of orexin receptors 1 and 2; structure in first source
sb 649868N-((1-((5-(4-fluorophenyl)-2-methyl-4-thiazolyl)carbonyl)-2-piperidinyl)methyl)-4-benzofurancarboxamide: antagonist of both orexin 1 and orexin 2 receptors; for treating insomnia; structure in first source
act-462206ACT-462206: an antagonist of both orexin 1 and oxexin 2 receptors; structure in first source
oroxin b
gsk 1059865
act-335827
orexin-a